SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001213900-23-077250
Filing Date
2023-09-18
Accepted
2023-09-18 12:21:48
Documents
3
Group Members
CLS THERAPEUTICS LTD.DMITRY GENKINGEORGY TETSM. SCOTT MAGUIREVICTOR TETS

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 TO SCHEDULE 13D ea185350-13da1cls_xeneticbio.htm SC 13D/A 94455
2 JOINT FILING AGREEMENT, DATED JUNE 14, 2023 ea185350ex99-1_xeneticbio.htm EX-1 13488
3 CONSENT OF M. SCOTT MAGUIRE ea185350ex99-2_xeneticbio.htm EX-2 2439
  Complete submission text file 0001213900-23-077250.txt   112162
Mailing Address 945 CONCORD ST. FRAMINGHAM MA 01701
Business Address 945 CONCORD ST. FRAMINGHAM MA 01701 781-778-7720
Xenetic Biosciences, Inc. (Subject) CIK: 0001534525 (see all company filings)

IRS No.: 452952962 | State of Incorp.: NV | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-89709 | Film No.: 231260591
SIC: 2834 Pharmaceutical Preparations

Mailing Address 180 VARICK STREET NEW YORK NY 10014
Business Address 180 VARICK STREET NEW YORK NY 10014 646-617-3088
CLS Therapeutics, LLC (Filed by) CIK: 0001951493 (see all company filings)

IRS No.: 920236145 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A